All 340B covered entities, including FQHCs (the ruling addresses manufacturers and the Secretary, and does not name FQHCs) • U.S. Court of Appeals for the D.C. Circuit • 2026-07-21
Challenge: Four manufacturers (Johnson & Johnson, Eli Lilly, Bristol Myers Squibb, Novartis) proposed in 2024 to stop providing 340B price reductions as upfront discounts and instead implement them as post-purchase rebates. HRSA responded that the Secretary had not provided for a rebate model and that proceeding would be inconsistent with the statute. The manufacturers sued, arguing they could unilaterally implement rebate models unless and until the Secretary disapproved them. The stakes for covered entities were cash-flow structural: an upfront discount reduces acquisition cost at purchase, while a rebate requires the entity to pay full price first and seek reimbursement afterward, with claims-level data submission and rejection risk attached.
Root Cause: The dispute turned on 42 U.S.C. § 256b(a)(1), which requires the Secretary to enter agreements under which the amount paid for covered outpatient drugs, 'taking into account any rebate or discount, as provided by the Secretary,' does not exceed the ceiling price. The manufacturers read the statute as silent on preapproval; the Secretary read 'as provided by the Secretary' as a preapproval requirement.
Resolution: The D.C. Circuit affirmed the district court in favor of the Secretary. Writing for the court, Circuit Judge Garcia held: 'Based on the statutory text and structure, we conclude that Section 340B requires the Secretary to provide for a rebate mechanism before manufacturers may implement one. And because it is undisputed that the Secretary has never authorized a mechanism encompassing the manufacturers' rebate models, the Secretary properly required the manufacturers to await his approval while he further studied their proposals.' The court also rejected the intervenors' broader argument that Section 340B permits no rebate mechanism at all, holding that rebate models ARE statutorily permissible — they simply require Secretarial preapproval.
Lesson: Do not read this as 340B stability. The ruling preserves the status quo on the mechanism while leaving the substantive question open and an HHS rebate pilot alive, which means a health center's 340B savings model still faces conversion risk on a timeline HHS controls. The concrete preparation is unglamorous: know whether your organization could operationally survive a rebate model — meaning whether you could fund full acquisition cost up front and produce claims-level data to substantiate rebate claims — and audit your patient-definition documentation and contract pharmacy agreements now, while the pressure is procedural rather than immediate.